Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

Sandro Wagner; Thomas Melchardt; Richard Greil

doi:10.1358/dot.2020.56.3.3107706

Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

Sandro Wagner (First author), Thomas Melchardt (Co-author), Richard Greil (Last author)

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	195-202
Journal	DRUGS OF TODAY
Volume	56
Issue number	3
DOIs	https://doi.org/10.1358/dot.2020.56.3.3107706
Publication status	Published - 2020

Keywords

ESSENTIAL THROMBOCYTHEMIA
SOMATIC MUTATIONS
LOW TOXICITY
RISK-FACTORS
JAK2
TRANSFORMATION
MYELOFIBROSIS
INTERFERONS
SURVIVAL
BURDEN

Access to Document

10.1358/dot.2020.56.3.3107706

Cite this

@article{227cd4b83a234110936d3ec9f05b1e84,

title = "Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.",

keywords = "ESSENTIAL THROMBOCYTHEMIA, SOMATIC MUTATIONS, LOW TOXICITY, RISK-FACTORS, JAK2, TRANSFORMATION, MYELOFIBROSIS, INTERFERONS, SURVIVAL, BURDEN",

author = "Sandro Wagner and Thomas Melchardt and Richard Greil",

note = "all: 3rd Medical Department with Hematology and Medical Oncology, Paracelsus Medical University Salzburg and Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria.",

year = "2020",

doi = "10.1358/dot.2020.56.3.3107706",

language = "English",

volume = "56",

pages = "195--202",

journal = "DRUGS OF TODAY",

issn = "1699-3993",

number = "3",

}

TY - JOUR

T1 - Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

AU - Wagner, Sandro

AU - Melchardt, Thomas

AU - Greil, Richard

N1 - all: 3rd Medical Department with Hematology and Medical Oncology, Paracelsus Medical University Salzburg and Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria.

PY - 2020

Y1 - 2020

KW - ESSENTIAL THROMBOCYTHEMIA

KW - SOMATIC MUTATIONS

KW - LOW TOXICITY

KW - RISK-FACTORS

KW - JAK2

KW - TRANSFORMATION

KW - MYELOFIBROSIS

KW - INTERFERONS

KW - SURVIVAL

KW - BURDEN

U2 - 10.1358/dot.2020.56.3.3107706

DO - 10.1358/dot.2020.56.3.3107706

M3 - Original Article

C2 - 32282866

SN - 1699-3993

VL - 56

SP - 195

EP - 202

JO - DRUGS OF TODAY

JF - DRUGS OF TODAY

IS - 3

ER -